Wednesday, April 2, 2025
4/2/2025
Enriching and Base-Resolution Profiling of 5-Methylcytosine in Degraded Clinical Samples - PROJECT SUMMARY The epigenome, centered around 5-methylcytosine (5mC), carries ample molecular signatures for understanding, detecting, and tracking tumorigenesis. However, 5mC profiling in clinical samples, such as formalin-fixed, paraffin-embedded (FFPE) tissues and cell-free DNA (cfDNA), is hindered by their limited quantity and degraded DNA. To address these challenges, this proposal describes development and application of the first glycosylase-based epigenome-sequencing platform. With superior sensitivity and fidelity, glycosylase- implemented epigenome sequencing (Glimp-seq) is poised to uncover the molecular underpinnings of tumorigenesis in low-volume degraded samples. Glimp-seq harnesses cascade enzymatic reactions involved in mammalian active demethylation—5mC oxidization by ten-eleven translocation dioxygenase (TET) and 5-carboxylcytosine (5caC) excision by thymine DNA glycosylase (TDG)—to convert 5mC into abasic sites. These abasic sites are subsequently functionalized by a thymine mimic to facilitate 5mC-specific enrichment and direct mutation detection (5mC-to-T). Glimp-seq represents a major advancement over current epigenome profiling methods, including bisulfite sequencing (BS- seq), enzymatic methyl sequencing (EM-seq), and TET-assisted pyridine borane sequencing (TAPS), by employing gentle, yet efficient, enzymatic conversions that preserve DNA integrity. As the specificity of the cascade TET/TDG reactions has been extensively optimized during natural evolution, Glimp-seq achieves unparalleled specificity for 5mC, reducing the risk of false positive detection. Unlike existing methods, Glimp-seq uniquely supports sequence-independent 5mC-specific enrichment, thereby increasing detection sensitivity. The resulting superior sensitivity and fidelity make Glimp-seq particularly suited for 5mC profiling in degraded clinical samples. In Aim 1, we will develop and rigorously benchmark Glimp-seq, using both synthetic and genomic DNA samples. We will compare Glimp-seq with BS-seq, EM-seq, and TAPS, and demonstrate its superiority using quantitative metrics. In Aim 2, we will apply Glimp-seq to two sets of clinical samples: ~140 FFPE cancer tissues from patients of prenatal exposure to diethylstilbestrol (known as DES daughters), which provides a unique opportunity to investigate synthetic estrogen-induced epigenetic inheritance; and cfDNA from 50 colorectal cancer patients, to showcase non-invasive detection of cancer-associated 5mC signatures. Successful implementation of Glimp-seq will transform the clinical practice of epigenome profiling by facilitating mechanistic studies using FFPE samples and by expediting early cancer diagnosis through cfDNA analysis. By freely distributing Glimp-seq reagents and protocols, we aim to support cancer researchers both locally and globally, fostering continuous advancements in understanding, detecting, and tracking cancer.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).